Cryoprecipitated anti-hemophiliac factor (Cryo) is transfused to patients for acquired hypofibrinogenemia, primarily due to blood loss. For the last several years, there has been a steadily increasing demand for Cryo. However, given the complexity and challenges of manufacturing Cryo, blood centers have been unable to keep up with increasing hospital demand. This supply-demand mismatch was acutely worsened due to COVID-19 related manufacturing disruptions, which has resulted in a critical shortage of the national Cryo inventory. Speakers will review current literature regarding fibrinogen replacement, and offer insights into usage trends that is driving the increased demand for Cryo. They will describe the current Cryo manufacturing challenges, especially focusing on the requirement to use FFP as the source material. This session will also dwell into solutions that the American Red Cross is considering, including consideration of manufacturing Cryo from PF24, rather than FFP.